Increasing prevalence of HIV-1 protease inhibitor-associated mutations correlates with long-term non-suppressive protease inhibitor treatment

Antiviral Research

Volumn 71, Issue 1, 2006, Pages 42-52

  Kagan, R M ^a   Cheung, P K ^b   Huard, T K ^a   Lewinski, M A ^a  

^a QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

^b BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

Author keywords

Comutation; Covariation; HIV 1; Protease inhibitors; Protease resistance mutations; Treatment duration

Indexed keywords

ABACAVIR; AMINO ACID; AMPRENAVIR; AMPRENAVIR PHOSPHATE; ATAZANAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; NEVIRAPINE; PROTEINASE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; TIPRANAVIR; ZALCITABINE; ZIDOVUDINE;

AMINO ACID SUBSTITUTION; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA BASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MUTATION; PREDICTION; PREVALENCE; PRIORITY JOURNAL; SCORING SYSTEM; TREATMENT DURATION;

AMINO ACID SEQUENCE; DATABASES; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; POINT MUTATION; PREVALENCE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL; SEQUENCE ANALYSIS, DNA; STATISTICS, NONPARAMETRIC; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 33745456662     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2006.02.008     Document Type: Article

References (42)

1. Alexander C.S., Dong W., Schechter M.T., O'Shaughnessy M.V., Strathdee S.A., Mo T., Montaner J.S., and Harrigan P.R. Prevalence of primary HIV drug resistance among seroconverters during an explosive outbreak of HIV infection among injecting drug users. AIDS 13 (1999) 981-985
2. Barbour J.D., Wrin T., Grant R.M., Martin J.N., Segal M.R., Petropoulos C.J., and Deeks S.G. Evolution of phenotypic drug susceptibility and viral replication capacity during long-term virologic failure of protease inhibitor therapy in human immunodeficiency virus-infected adults. J. Virol. 76 (2002) 11104-11112
3. Baxter J.D., Mayers D.L., Wentworth D.N., Neaton J.D., Hoover M.L., Winters M.A., Mannheimer S.B., Thompson M.A., Abrams D.I., Brizz B.J., Ioannidis J.P., and Merigan T.C. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS 14 (2000) F83-F93
4. Benjamini Y., and Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. JR. Stat. Soc. Ser. B. Stat. Methodol. 57 (1995) 289-300
5. Ceccherini-Silberstein F., Erba F., Gago F., Bertoli A., Forbici F., Bellocchi M.C., Gori C., D'Arrigo R., Marcon L., Balotta C., Antinori A., Monforte A.D., and Perno C.F. Identification of the minimal conserved structure of HIV-1 protease in the presence and absence of drug pressure. AIDS 18 (2004) F11-F19
6. Chen L., Perlina A., and Lee C.J. Positive selection detection in 40,000 human immunodeficiency virus (HIV) type 1 sequences automatically identifies drug resistance and positive fitness mutations in HIV protease and reverse transcriptase. J. Virol. 78 (2004) 3722-3732
7. Cheung P.K., Wynhoven B., and Harrigan P.R. Which HIV-1 drug resistance mutations are common in clinical practice?. AIDS Rev. 6 (2004) 107-116
8. Condra J.H., Schleif W.A., Blahy O.M., Gabryelski L.J., Graham D.J., Quintero J.C., Rhodes A., Robbins H.L., Roth E., Shivaprakash M., Titus D., Yang T., Tepplert H., Squires K.E., Deutsch P.J., and Emini E.A. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374 (1995) 569-571
9. Deeks S.G., Smith M., Holodniy M., and Kahn J.O. HIV-1 protease inhibitors. A review for clinicians. JAMA 277 (1997) 145-153
10. Devereux H.L., Emery V.C., Johnson M.A., and Loveday C. Replicative fitness in vivo of HIV-1 variants with multiple drug resistance-associated mutations. J. Med. Virol. 65 (2001) 218-224
11. Doyon L., Tremblay S., Bourgon L., Wardrop E., and Cordingley M.G. Selection and characterization of HIV-1 showing reduced susceptibility to the non-peptidic protease inhibitor tipranavir. Antiviral Res. 68 (2005) 27-35
12. Fitch W.M., and Margoliash E. Construction of phylogenetic trees. Science 155 (1967) 279-284
13. Hertogs K., Bloor S., Kemp S.D., Van den Eynde C., Alcorn T.M., Pauwels R., Van Houtte M., Staszewski S., Miller V., and Larder B.A. Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples. AIDS 14 (2000) 1203-1210
14. Hirsch M.S., Brun-Vezinet F., Clotet B., Conway B., Kuritzkes D.R., D'Aquila R.T., Demeter L.M., Hammer S.M., Johnson V.A., Loveday C., Mellors J.W., Jacobsen D.M., and Richman D.D. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin. Infect. Dis. 37 (2003) 113-128
15. Hoffman N.G., Schiffer C.A., and Swanstrom R. Covariation of amino acid positions in HIV-1 protease. Virology 314 (2003) 536-548 Erratum in: Virology 2005. 331, 206-207
16. Hogg R.S., Yip B., Chan K.J., Wood E., Craib K.J., O'Shaughnessy M.V., and Montaner J.S. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA 286 (2001) 2568-2577
17. Hong L., Zhang X.C., Hartsuck J.A., and Tang J. Crystal structure of an in vivo HIV-1 protease mutant in complex with saquinavir: insights into the mechanisms of drug resistance. Protein Sci. 9 (2000) 1898-1904
18. Johnson V.A., Brun-Vezinet F., Clotet B., Conway B., Kuritzkes D.R., Pillay D., Schapiro J., Telenti A., and Richman D. Update of the drug resistance mutations in HIV-1: 2005. Top. HIV Med. 13 (2005) 51-57
19. Johnson V.A., Brun-Vezinet F., Clotet B., Conway B., Kuritzkes D.R., Pillay D., Schapiro J.M., Telenti A., and Richman D.D. Update of the drug resistance mutations in HIV-1: Fall 2005b. Top. HIV Med. 13 (2005) 125-131
20. Kagan R., Winters M., Merigan T., and Heseltine P. HIV type 1 genotypic resistance in a clinical database correlates with antiretroviral utilization. AIDS Res. Hum. Retrov. 20 (2004) 1-9
21. Kagan R., Winters M., Merigan T., and Heseltine P. Large scale cluster analysis of HIV-1 protease mutations in a clinical database. Antiviral Ther. 9 (2004) S92
22. Kantor R., Shafer R.W., Follansbee S., Taylor J., Shilane D., Hurley L., Nguyen D.P., Katzenstein D., and Fessel W.J. Evolution of resistance to drugs in HIV-1-infected patients failing antiretroviral therapy. AIDS 18 (2004) 1503-1511
23. Kohl N.E., Emini E.A., Schleif W.A., Davis L.J., Heimbach J.C., Dixon R.A., Scolnick E.M., and Sigal I.S. Active human immunodeficiency virus protease is required for viral infectivity. Proc. Natl. Acad. Sci. USA 85 (1988) 4686-4690
24. Maguire M., Shortino D., Klein A., Harris W., Manohitharajah V., Tisdale M., Elston R., Yeo J., Randall S., Xu F., Parker H., May J., and Snowden W. Emergence of resistance to protease inhibitor amprenavir in human immunodeficiency virus type 1-infected patients: selection of four alternative viral protease genotypes and influence of viral susceptibility to coadministered reverse transcriptase nucleoside inhibitors. Antimicrob. Agents Chemother. 46 (2002) 731-738
25. Martinez-Picado J., Savara A.V., Sutton L., and D'Aquila R.T. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1. J. Virol. 73 (1999) 3744-3752
26. Morgan E., Tisdale M., Maguire M., Macmanus S., Yates P., Griffin P., Xu F., Elston R., Kleim J.P., Pillay D., and Cane P. The HIV-1 protease mutation K55R is associated with the presence of the M46I/L mutation. Antiviral Ther. 8 (2003) S57
27. Mueller S.M., Daeumer M., Kaiser R., Walter H., Colonno R., and Korn K. Susceptibility to saquinavir and atazanavir in highly protease inhibitor (PI) resistant HIV-1 is caused by lopinavir-induced drug resistance mutation L76V. Antiviral Ther. 9 (2004) S44
28. Novak R.M., Chen L., MacArthur R.D., Baxter J.D., Huppler Hullsiek K., Peng G., Xiang Y., Henely C., Schmetter B., Uy J., van den Berg-Wolf M., Kozal M., and Terry Beirn Community Programs for Clinical Research on AIDS 058 Study Team. Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, treatment-naive patients: implications for routine resistance screening before initiation of antiretroviral therapy. Clin. Infect. Dis. 40 (2005) 468-474
29. Patick A.K., Duran M., Cao Y., Shugarts D., Keller M.R., Mazabel E., Knowles M., Chapman S., Kuritzkes D.R., and Markowitz M. Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir. Antimicrob. Agents Chemother. 42 (1998) 2637-2644
30. Palella Jr. F.J., Delaney K.M., Moorman A.C., Loveless M.O., Fuhrer J., Satten G.A., Aschman D.J., and Holmberg S.D. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. 338 (1998) 853-860
31. Peng C., Ho B.K., Chang T.W., and Chang N.T. Role of human immunodeficiency virus type 1-specific protease in core protein maturation and viral infectivity. J. Virol. 63 (1989) 2550-2556
32. Pillay D., Green H., Matthias R., Dunn D., Phillips A., Sabin C., Evans B., and U.K. Collaborative Group on HIV Drug Resistance. Estimating HIV-1 drug resistance in antiretroviral-treated individuals in the United Kingdom. J. Infect. Dis. 192 (2005) 967-973
33. Resch W., Parkin N., Watkins T., Harris J., and Swanstrom R. Evolution of human immunodeficiency virus type 1 protease genotypes and phenotypes in vivo under selective pressure of the protease inhibitor ritonavir. J. Virol. 79 (2005) 10638-10649
34. Rhee S.Y., Fessel W.J., Zolopa A.R., Hurley L., Liu T., Taylor J., Nguyen D.P., Slome S., Klein D., Horberg M., Flamm J., Follansbee S., Schapiro J.M., and Shafer R.W. HIV-1 Protease and reverse-transcriptase mutations: correlations with antiretroviral therapy in subtype B isolates and implications for drug-resistance surveillance. J. Infect. Dis. 192 (2005) 456-465
35. Saitou N., and Nei M. The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol. Biol. Evol. 4 (1987) 406-425
36. Shafer R.W., Kantor R., and Gonzales J. The genetic basis of HIV-1 reverse transcriptase and protease inhibitors. AIDS Rev. 2 (2000) 211-228
37. Sugiura W., Matsuda Z., Yokomaku Y., Hertogs K., Larder B., Oishi T., Okano A., Shiino T., Tatsumi M., Matsuda M., Abumi H., Takata N., Shirahata S., Yamada K., Yoshikura H., and Nagai Y. Interference between D30N and L90M in selection and development of protease inhibitor-resistant human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 46 (2002) 708-715
38. Svicher V., Ceccherini-Silberstein F., Erba F., Santoro M., Gori C., Bellocchi M.C., Giannella S., Trotta M.P., Monforte A., Antinori A., and Perno C.F. Novel human immunodeficiency virus type 1 protease mutations potentially involved in resistance to protease inhibitors. Antimicrob. Agents Chemother. 49 (2005) 2015-2025
39. Tamalet C., Fantini J., Tourres C., and Yahi N. Resistance of HIV-1 to multiple antiretroviral drugs in France: a 6-year survey (1997-2002) based on an analysis of over 7000 genotypes. AIDS 17 (2003) 2383-2388
40. Weinstock H.S., Zaidi I., Heneine W., Bennett D., Garcia-Lerma J.G., Douglas Jr. J.M., LaLota M., Dickinson G., Schwarcz S., Torian L., Wendell D., Paul S., Goza G.A., Ruiz J., Boyett B., and Kaplan J.E. The epidemiology of antiretroviral drug resistance among drug-naïve HIV-1-infected persons in 10 US cities. J. Infect. Dis. 189 (2004) 2174-2180
41. Wensing A.M., van de Vijver D.A., Angarano G., Asjo B., Balotta C., Boeri E., Camacho R., Chaix M.L., Costagliola D., De Luca A., Derdelinckx I., Grossman Z., Hamouda O., Hatzakis A., Hemmer R., Hoepelman A., Horban A., Korn K., Kucherer C., Leitner T., Loveay C., MacRae E., Maljkovic I., de Mendoza C., Meyer L., Nielsen C., Op de Coul E.L., Ormaasen V., Paraskevis D., Perrin L., Puchhammer-Stockl E., Ruiz L., Salminen M., Schmit J.C., Schneider F., Schuurman R., Soriano V., Stanczak G., Stanojevic M., Vandamme A.M., Van Laethem K., Violin M., Wilbe K., Yerly S., Zazzi M., Boucher C.A., and SPREAD Programme. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J. Infect. Dis. 192 (2005) 958-966
42. Wu T.D., Schiffer C.A., Gonzales M.J., Taylor J., Kantor R., Chou S., Israelski D., Zolopa A.R., Fessel W.J., and Shafer R.W. Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments. J. Virol. 77 (2003) 4836-4847